Pay in 4 interest-free payments of $6.64 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Current clinical evidence from a meta-analysis of phase 2 and three studies of tirzepatide in participants with T2D indicates that tirzepatide treatment is not associated with an increased risk of MACE-4, a composite outcome comprising the four outcomes cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and hospitalization due to unstable angina (HR = 0.80
Your clinician can help determine which option makes the most sense for you
Conditions like fatty liver disease or rapid fat breakdown can make this effect stronger
Selenium in bodily homeostasis: hypothalamus, hormones, and highways of communication
If future studies confirm these findings in humans, it could mean a major shift in how doctors treat breast cancer in patients who are overweight or obese
